Navigation Links
BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

A new drug, peramivir, claimed to be a highly potent formulation for combating the virulent forms of the H5N1 bird flu virus has been credited with a fast-track review by the Food and Drug Administration. //

This novel drug, produced by the pharmaceutical company BioCryst can be injected intravenously. Promising results have been obtained from drug trials conducted against different bird flu strains. If successful and approved we could soon have a new form of anti-viral therapy to effectively manage the bird flu threat.

"The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza," said BioCryst Chairman and CEO Charles Bugg.

The FDA had approved the launch of human trials to test the efficacy and safety of the intravenous formulation of peramivir, last December. Following approval, it has been planned to initiate phase I clinical trials of the drug within March 2006. The drug would be tested on patients suffering from acute influenza infection.

In addition, developing an intramuscular form of the drug is also under consideration. This is belived to be tested on victims of seasonal bird flu. Both the clinical trials are jointly conducted by the National Institutes of Allergy and Infectious Diseases at the National Institute of Health.

Only those drugs, used for the treatment of severe diseases for which there is an unfulfiled medical need would be granted fast-track status by the FDA. A six month review of the sponsor’s drug by the FDA would also be included in the fast-track package.


'"/>




Page: 1

Related medicine news :

1. Rural Population Enjoys Better Mental Health
2. Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again)
3. Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses
4. US Reviews Risks Of Tamiflu After 12 Children Die
5. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
6. FDA Accords Priority Review For Pediatric Crohns Disease Drug
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Review of Pramod Mahajans Injuries
9. Vaticans Council Reviews Condom Usage
10. Review of Reversal of Spread of Diseases in Africa
11. Closure of NHS Borders Hospitals to be Reviewed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, ... it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the ... oral health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that ... the event they are experiencing an illness. Migraines are a severe form of a ... with migraines would not wish the pain on their worst enemy, the feeling can ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
(Date:2/4/2016)... 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... entered into a settlement agreement with the United ... the SEC,s investigation into possible violations of the ... of the settlement agreement, SciClone has agreed to ... pre-judgment interest and a penalty.  This payment is ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
Breaking Medicine Technology: